Search

Displaying results 4231 - 4240 of 10000 in total
  1. Drug

    Eptifibatide

    go.drugbank.com/drugs/DB00063
    ApprovedInvestigational

    Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide th...

  2. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    It is used in prostate cancer treatment.

  3. Drug

    Ruplizumab

    go.drugbank.com/drugs/DB06475
    Investigational

    Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

  4. Drug

    Nitric Oxide

    go.drugbank.com/drugs/DB00435
    ApprovedInvestigational

    This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. … It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.

    Categories: Compounds used in a research, industrial, or household settingProducts: GNO Refreshing Mist (For skin care, and dry skin, safe to use it in the eye, Acne treatment, Fermented Sunflower seed Extract), Renair Renaissance In Hair (Prevents hairloss, fermented lettuce, garlic, bean, cabbage, cricket greentea leaf,mulberry branch, leaf, and roots extract)
  5. Drug

    Tetracosactide

    go.drugbank.com/drugs/DB01284
    ApprovedInvestigational

    ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. … The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.

  6. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.

  7. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  8. Drug

    L-tartaric acid

    go.drugbank.com/drugs/DB09459
    Approved

    Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics

    Mixtures: E-Z-gas 2 Granules
  9. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  10. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.